Leukemia Articles | Page 3

Combinations Continue to Push CLL Field Forward
Jacqueline C. Barrientos, MD, discusses recent combination trials in CLL, and emerging agents in the pipeline.
FDA Panel to Review Blinatumomab Application for MRD-positive ALL
The FDA's Oncologic Drugs Advisory Committee is slated to review a supplemental biologics license application for the use of blinatumomab for the treatment of patients with minimal residual disease-positive B-cell precursor acute lymphoblastic leukemia.
FDA Grants Priority Review to Ivosidenib for IDH1+ AML
The FDA has granted a priority review designation to ivosidenib (AG-120) for the treatment of patients with relapsed/refractory IDH1-mutant acute myeloid leukemia.
O'Brien Covers Evolution of Ibrutinib in CLL
Susan O’Brien, MD, discusses the impact that has been seen with ibrutinib following the long-term follow-up of the RESONATE studies in chronic lymphocytic leukemia. 
FDA Approval Sought for Duvelisib in CLL, Follicular Lymphoma
A new drug application has been submitted to the FDA for duvelisib for a full approval for relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and an accelerated approval in relapsed/refractory follicular lymphoma.
Frontline Venetoclax Shows Promise in Elderly AML Patients
Venetoclax (Venclexta) in combination with a hypomethylating agent induced complete remissions in 61% of patients aged 65 years or older with previously untreated acute myeloid leukemia.
Vemurafenib/Rituximab Combo Reaches 100% CR Rate in Hairy Cell Leukemia
Enrico Tiacci, MD, discusses the high potential with the combination of vemurafenib and rituximab in relapsed/refractory patients with hairy cell leukemia.
FLT3 Inhibitors Continue to Move Through AML Pipeline
Catherine Smith, MD, discusses the evolution of FLT3 inhibition in AML and ongoing studies that are poised to potentially change practice.
Novel Agents Advance Field of AML
Gabriel Mannis, MD, discusses novel therapies shifting the treatment paradigm for patients with AML.
FDA Approves Arsenic Trioxide for Promyelocytic Leukemia
The FDA has approved arsenic trioxide (Trisenox) in combination with the all-trans retinoic acid agent tretinoin for the treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia with the t(15;17) translocation or PML-RARA gene expression.
Publication Bottom Border
Border Publication